Samer Al Hadidi

Sourced from institutional research profiles (UAMS TRI or ARA).

Associate Professor , Clinical Director of Amyloidosis Program

UAMS

Also affiliated: Houston Methodist (2021); The University of Texas MD Anderson Cancer Center (2020–2022); Baylor College of Medicine (2018–2022); Columbia University Irving Medical Center (2023); University of Arkansas Medical Center (2021–2025); Hurley Medical Center (2016–2018); Texas Children's Hospital (2021); Herbert Irving Comprehensive Cancer Center (2023); Dan L Duncan Comprehensive Cancer Center (2021); Harold C. Simmons Comprehensive Cancer Center (2025–2026); Indiana University School of Medicine (2023); The University of Texas Southwestern Medical Center (2025–2026); Michigan State University (2014–2018)

22 h-index 263 pubs 1,923 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Samer Al Hadidi's research focuses on plasma cell disorders, including multiple myeloma and light chain amyloidosis, as well as cellular therapies such as CAR T-cell therapy and hematopoietic stem cell transplantation. He has investigated the risks of infections associated with bispecific antibodies in multiple myeloma, with findings published in 2023. His work also addresses disparities in clinical trial participation, including the participation of Black Americans and African Americans in cancer clinical trials, with publications in 2020, 2021, and 2022.

Dr. Al Hadidi has explored the immune microenvironment in multiple myeloma progression at a single-cell level, publishing on this topic in 2022. He has also characterized the changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma, with research published in 2023. He has also contributed to understanding how to treat high-risk myeloma at diagnosis and relapse, with a publication in 2021. His scholarly output includes 260 publications and an h-index of 22, with 1,905 citations.

He collaborates with researchers at the University of Arkansas for Medical Sciences, including Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, and Carolina Schinke, with whom he shares numerous publications. Dr. Al Hadidi is the Clinical Director of the Amyloidosis Program at UT Southwestern Medical Center and serves as Leader of the Fellows’ Plasma Cell Disorders Clinic.

Metrics

h-index: 22
Publications: 263
Citations: 1,923

Positions

Associate Professor , Clinical Director of Amyloidosis Program 2025–present

The University of Texas Southwestern Medical Center Internal Medicine ORCID
Associate Professor , Clinical Director of Amyloidosis Program publications 2021–2026

University of Arkansas for Medical Sciences Institutional directory
Assistant Professor 2021–2025

University of Arkansas for Medical Sciences Myeloma ORCID

Selected Publications

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal 1 citation DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

Blood Cancer Journal 2 citations DOI OpenAlex
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma (2025)

Blood 11 citations DOI OpenAlex
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)

Blood Cancer Journal 19 citations DOI OpenAlex
Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis (2025)

Clinical Hematology International 2 citations DOI OpenAlex
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort (2025)

British Journal of Haematology 7 citations DOI OpenAlex
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)

Blood Advances 5 citations DOI OpenAlex
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)

Blood Advances 1 citation DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

Cancer Biomarkers 1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

JAMA Oncology 7 citations DOI OpenAlex
Current and Future Directions of Immunotherapies in Multiple Myeloma (2025)

American Society of Clinical Oncology Educational Book 1 citation DOI OpenAlex
Bispecific antibody therapy in central nervous system (CNS) multiple myeloma (MM): Multicenter retrospective study. (2025)

Journal of Clinical Oncology 2 citations DOI OpenAlex
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 1 citation DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients Caelum Biosciences, Inc via IQVIA, Inc.
276346 S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance SouthWest Oncology Group
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA Pfizer, Inc.